References
- Liao J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:409–24.
- Kurup S, Dineley K, Malaiyandi L, et al. Drugs to treat head and neck cancers: mechanisms of action. In: Radosevich J, ed. Head & neck cancer: current perspectives, advances, and challenges. Springer: Dordrecht; 2013: 861–913.
- Song Z, Ge Y, Wang C, et al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer. J Med Chem 2016;59:6580–94.
- Chong C, Janne P. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389–400.
- Mehra R, Serebriiskii I, Burtness B, et al. Aurora kinases in head and neck cancer. Lancet Oncol 2013;14:e425–35.
- Hoellein A, Pickhard A, von Keitz F, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011;2:599–609.
- Astsaturov I, Ratushny V, Sukhanova A, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010;3:ra67.
- Chen J, Lu H, Zhou W, et al. AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827. Oncol Rep 2015;33:1860–6.
- Zhang J, Pan X, Astsaturov IA, et al. Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2011;29:e13038.
- Knight Z, Lin H, Shokat K. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130–7.
- Zhu W, Chen H, Wang Y, et al. Design, synthesis, and pharmacological evaluation of novel multisubstituted pyridin-3-amine derivatives as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer. J Med Chem 2017;60:6018–35.
- Wood E, Truesdale A, McDonald O, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652–9.
- Gangjee A, Kurup S, Ihnat M, et al. N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. Bioorg Med Chem 2012;20:910–14.
- Gangjee A, Kurup S, Ihnat M, et al. Synthesis and biological activity of N4-phenylsubstituted-6-(2,4-dichlorophenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem 2010;18:3575–87.
- Grotzfeld R, Patel H, Mehta S, et al. Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases. US 2005/0153989 A1 20050714.
- Traxler P, Guido B, Karl-Diether W, Joerg F. Preparation of 7H-pyrrolo[2,3-d]pyrimidines as tyrosine protein kinase inhibitors. PCT Int Appl 1997; WO 9702266 A1.
- Gangjee A, Zaware N, Raghavan S, et al. N4-(3-Bromophenyl)-7-(substitutedbenzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis and in vivo evaluation. Bioorg Med Chem 2012;20:2444–54.
- Cheng H, Nair S, Murray B, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants. J Med Chem 2016;59:2005–24.
- Le Brazidec J, Pasis A, Tam B, et al. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as aurora kinase inhibitors. Bioorg Med Chem Lett 2012;22:4033–7.
- Kawakita Y, Seto M, Ohashi T, et al. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorg Med Chem 2013;21:2250–61.
- Bavetsias V, Faisal A, Crumpler S, et al. Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells. J Med Chem 2013;56:9122–35.
- Molecular Operating Environment (MOE 2016.08), Chemical Computing Group, Inc, 1255 University St., Suite 1600, Quebec, Canada, H3B3X3; 2017.
- Zegzouti H, Zdanovskaia M, Hsiao K, Goueli S. ADP-Glo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol 2009;7:560–72.
- Fabian M, Biggs W, Treiber D, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329–36.
- Addepalli M, Ray K, Kumar B, et al. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther 2010;17:352–9.